{"id":"cetermin","rwe":[],"tags":[{"label":"Small Molecule","category":"modality"},{"label":"Active","category":"status"}],"phase":"marketed","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=CETERMIN","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T00:18:07.140515+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T00:18:12.830517+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=CETERMIN","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T00:18:13.209595+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL2108269/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:18:13.904581+00:00"}},"allNames":["cetermin"],"offLabel":[],"synonyms":[],"timeline":[],"approvals":[],"ecosystem":[],"mechanism":{"modality":"Small Molecule","explanation":"","oneSentence":"","technicalDetail":"The technical details of cetermin's mechanism of action are not publicly disclosed, but it is classified as a small molecule modality, suggesting it may interact with proteins or other biomolecules to produce its effects."},"commercial":{},"references":[{"id":1,"url":"https://clinicaltrials.gov/search?intr=cetermin","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=cetermin","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-31T10:33:43.199676","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:18:15.522383+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"competitors":[],"genericName":"cetermin","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT06579196","phase":"PHASE1,PHASE2","title":"Trabedersen (OT-101) With Pembrolizumab for Newly Diagnosed Advanced NSCLC and Positive PD-L1","status":"RECRUITING","sponsor":"University of Nebraska","startDate":"2025-05-12","conditions":["Non-small Cell Lung Cancer"],"enrollment":45,"completionDate":"2029-02"},{"nctId":"NCT04233463","phase":"NA","title":"The Effect of Oral Polymeric Diet Enriched With TGF-beta 2 (Modulen) on Clinical Response and Mucosal Healing in Adult Patients With Newly Diagnosed Crohn's Disease","status":"UNKNOWN","sponsor":"Hillel Yaffe Medical Center","startDate":"2020-01","conditions":["Crohn Disease"],"enrollment":50,"completionDate":"2021-06"},{"nctId":"NCT00844064","phase":"PHASE1","title":"Safety and Tolerability of AP 12009, Administered I.V. in Patients With Advanced Tumors Known to Overproduce TGF-beta-2","status":"COMPLETED","sponsor":"Isarna Therapeutics GmbH","startDate":"2005-01","conditions":["Pancreatic Neoplasms","Melanoma","Colorectal Neoplasms"],"enrollment":62,"completionDate":"2011-11"},{"nctId":"NCT00761280","phase":"PHASE3","title":"Efficacy and Safety of AP 12009 in Patients With Recurrent or Refractory Anaplastic Astrocytoma or Secondary Glioblastoma","status":"TERMINATED","sponsor":"Isarna Therapeutics GmbH","startDate":"2008-12","conditions":["Anaplastic Astrocytoma","Glioblastoma"],"enrollment":27,"completionDate":"2012-06"},{"nctId":"NCT00431561","phase":"PHASE2","title":"Phase IIb Clinical Trial With TGF-β2 Antisense Compound AP 12009 for Recurrent or Refractory High-grade Glioma","status":"COMPLETED","sponsor":"Isarna Therapeutics GmbH","startDate":"2003-04","conditions":["Glioblastoma","Anaplastic Astrocytoma"],"enrollment":141,"completionDate":"2009-03"},{"nctId":"NCT01058785","phase":"PHASE2","title":"Phase II Study of Lucanix™ in Patients With Stages II-IV Non-Small Cell Lung Cancer","status":"COMPLETED","sponsor":"NovaRx Corporation","startDate":"2003-03","conditions":["Lung Neoplasm","Carcinoma, Bronchogenic"],"enrollment":75,"completionDate":"2005-12"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"chemblId":"CHEMBL2108269"},"formularyStatus":[],"_enricherVersion":"v2-openfda","developmentCodes":[],"ownershipHistory":[],"publicationCount":0,"therapeuticAreas":["Other"],"biosimilarFilings":[],"recentPublications":[],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","brandName":"CETERMIN","companyName":"","companyId":"","modality":"Recombinant protein","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:18:15.522383+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"enriching","dataCompleteness":{"mechanism":false,"indications":false,"safety":false,"trials":true,"score":1}}